Skip to content
10-Q

Quarterly Report

Oyster Point Pharma, Inc.

0001720725-21-000095

← back to feed
Filed
Nov 4, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2021 · Oct 29, 2021 26.16M sh
Long Term Debt Q3 2021 · Sep 30, 2021 $41.92M
Long Term Debt Q3 2021 · Dec 31, 2020 $0
Current Liabilities Q3 2021 · Sep 30, 2021 $15.16M
Current Liabilities Q3 2021 · Dec 31, 2020 $10.98M
Total Liabilities Q3 2021 · Sep 30, 2021 $57.5M
Total Liabilities Q3 2021 · Dec 31, 2020 $11.25M
Current Assets Q3 2021 · Sep 30, 2021 $189.69M
Current Assets Q3 2021 · Dec 31, 2020 $196.37M
Total Assets Q3 2021 · Sep 30, 2021 $195.01M
Total Assets Q3 2021 · Dec 31, 2020 $197.91M
Cash And Equivalents Q3 2021 · Dec 31, 2020 $192.59M
Cash And Equivalents Q3 2021 · Sep 30, 2020 $214.33M
Shares Diluted Q3 2021 · Sep 30, 2020 25.8M sh
Shares Diluted Q3 2021 · Sep 30, 2020 23.54M sh
Capex Q3 2021 · Sep 30, 2020 $342K
Operating Cash Flow Q3 2021 · Sep 30, 2020 −$37.35M
Stockholders Equity Q3 2021 · Sep 30, 2020 $206.67M
Stockholders Equity Q3 2021 · Jun 30, 2020 $220.82M
Stockholders Equity Q3 2021 · Mar 31, 2020 $121.96M
Stockholders Equity Q3 2021 · Dec 31, 2019 $137.3M
Eps Diluted Q3 2021 · Sep 30, 2020 −$0.63
Eps Diluted Q3 2021 · Sep 30, 2020 −$2.05
Eps Basic Q3 2021 · Sep 30, 2020 −$0.63
Eps Basic Q3 2021 · Sep 30, 2020 −$2.05
Sga Expense Q3 2021 · Sep 30, 2020 $8.11M
Sga Expense Q3 2021 · Sep 30, 2020 $20.64M
Rd Expense Q3 2021 · Sep 30, 2020 $8.21M
Rd Expense Q3 2021 · Sep 30, 2020 $28.1M
Net Income Q3 2021 · Sep 30, 2020 −$16.31M
Net Income Q3 2021 · Sep 30, 2020 −$48.29M
Net Income Q3 2021 · Jun 30, 2020 −$15.46M
Net Income Q3 2021 · Mar 31, 2020 −$16.52M
Operating Income Q3 2021 · Sep 30, 2020 −$16.32M
Operating Income Q3 2021 · Sep 30, 2020 −$48.75M
Revenue Q3 2021 · Sep 30, 2020 $0
Revenue Q3 2021 · Sep 30, 2020 $0